Policy Correspondence Archive
CSRO has templates available for rheumatology practices to contact insurers and other payers here.
- CSRO Letter RE: Nondiscrimination in Health Programs and Activities (1557 NPRM (RIN 0945-AA17))
September 21, 2022 - CSRO Letter RE: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy in Rheumatoid Arthritis (DL39424)
September 17, 2022 - CSRO Letter RE: Requests for Information (RFI) on the Medicare Advantage Program
August 30, 2022 - CSRO Letter RE: Medicare and Medicaid Programs; CY 2023 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment Policies
August 25, 2022 - CSRO Letter RE: FTC-2022-0015-0001
May 12, 2022 - CSRO Letter RE: Proposed Rules for 28 TAC §19.1730 - 19.1733 & 28 TAC §12.601 relating to the Prior Authorization Exemptions
May 9, 2022 - CSRO Letter RE: Call for Public Comment on Wave 5 Measure Development – Rheumatoid Arthritis
March 25, 2022 - CSRO Letter RE: Predictive Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis Contractor Advisory Committee (CAC)
January 31, 2022 - Correspondence between CSRO and Blue Cross Blue Shield of South Carolina Re: Non-Medical Switching Policy Update Concerns
- Initial Letter from CSRO to Blue Cross Blue Shield (December 13, 2021)
- Response from Blue Cross Blue Shield (December 17, 2021)
- Follow-up Letter from CSRO to Blue Cross Blue Shield (January 18, 2022)
- CSRO Letter to Edward Jones RE: White Bagging
September 15, 2021 - CSRO Letter RE: Medicare Program; CY 2022 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies
September 13, 2021 - CSRO Letter RE: Request for Information Regarding Reporting on Pharmacy Benefits and Prescription Drug Costs, CMS-9905-NC
July 21, 2021 - CSRO Letter RE: 114CSR99 Pharmacy Auditing Entities and Pharmacy Benefit Managers
July 1, 2021 - CSRO Letter RE: Local Coverage Article (LCA) titled Billing and Coding: Complex Drug Administration (A58544, A58532 & A58533, A58527, A58526, A58620)
May 27, 2021 - CSRO Letter RE: Support for the Improving Seniors' Timely Access to Care Act
May 14, 2021 - CSRO Letter to Centers for Medicare & Medicaid Services (CMS) RE: Existing and Emerging Issues with Medicare's Self-Administered Drug (SAD) List
April 29, 2021 - CSRO Letter RE: Call for Comment on Wave 4 Measure Development – Rheumatoid Arthritis
February 5, 2021 - CSRO Memo re Recent Complaints about Vivio Practices
February 26, 2020 - CSRO Comments RE: UHC December Bulletin announcement to change the medical benefits for commercial and community plan patients who are currently stable on REMICADE® (infliximab)
December 22, 2020 - CSRO Comments RE: CMS-5528-IFC, “Most Favored Nation Model” interim final rule with comment period
December 14, 2020 - CSRO Comments RE: CMS-2842-P (Medicaid AMP Calculation)
July 15, 2020 - CSRO Press Release Re: Implementation of BCBST White-bagging Policy
July 1, 2020 - CSRO Press Release Re: Patient Impact of BCBST White-bagging Policy
June 23, 2020 - CSRO Press Release Re: Tennessee Employers Adopting BCBST White-bagging Policy
June 18, 2020 - CSRO Letter to TN Chamber of Commerce re: BCBST White-bagging Policy
June 11, 2020 - CSRO Letter to BCBST re: Mandatory White-bagging
June 5, 2020 - CSRO Comments to CMS re: COVID-19 Telehealth and Home Administration Services
April 27, 2020 - CSRO Memo to MACs Re: Addition of Stelara to SAD List
April 22, 2020 - CSRO’s Compounding HCQ Letter to HHS
April 14, 2020 - CSRO Joint Letter to CMS Re: Addition of Stelara to SAD List
April 8, 2020 - CSRO Submits HR 3 Comments
November 26, 2019 - CSRO Submits IPI Comments
December 31, 2018 - CSRO Memo to UHG RE: Downcoding for Infusion Administration Services
October 22, 2018 - CSRO Comments on CAP RFI OPPS
September 25, 2018 - CSRO Comments to CMS on 2019 MPFS QPP NPRM
September 10, 2018 - CSRO Biosimilar Pass-Through Support - Memo to Congress
March 15, 2018 - Comments by CSRO and Cosignatories to Anthem on HA Injections
September 26, 2017 - Comments by the CSRO on the Medicare Physician Fee Schedule (CMS-1676-P) Proposed Revisions
September 11, 2017 - H.B. 260 – Relating to the regulation of biosimilar medications
February 6, 2017
Archive of Correspondence from Partners of CSRO
- ASM Letter RE: FTC-2022-0015-0001
May 17, 2022 - ATAP Letter RE: FTC-2022-0015-0001
May 11, 2022 - ASM Letter RE: Recommendations to Improve Utilization Management and Advance Specialty-Focused Alternative Payment Models
April 25, 2022 - Letter RE: Oregon Waiver Renewal Application
April 11, 2022 - ASM Letter RE: Request for Information: Electronic Prior Authorization Standards, Implementation Specifications, and Certification Criteria
March 18, 2022 - ASM Letter RE: Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (CMS-2022-0021)
March 4, 2022 - ASM Letter RE: Request for Congressional Hearings on MACRA
February 18, 2022 - ACCC Letter RE: Comments on HHS Notice of Benefit and Payment Parameters for 2023 Proposed Rule, CMS-9911-P RIN 0938-AU65
January 27, 2022 - ASM Letter RE: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2023
January 27, 2022 - Letter RE: Support for S.644 and H.1053
January 27, 2022 - Letter RE: Support for LD 1783
January 25, 2022 - ASM Letter RE: Patient Protection and Affordable Care Act; Updating Payment Parameters, Section 1332 Waiver Implementing Regulations, and Improving Health Insurance Markets for 2022 and Beyond Proposed Rule
July 28, 2021 - Rheumatology Community Letter RE: The Elijah E. Cummings Lower Drug Costs Now Act
May 13, 2021 - CRA Letter to Anthem Re Whitebagging SPP Mandate
October 26, 2020